Rituximab Works for Some ChildrendailyRxRecent studies have identified rituximab (sold as Rituxan) as a possible treatment for a childhood kidney disorder. The drug may allow children to stop taking the standard drug treatment, which can be toxic. Ritu…
Genérico para transplantadosLa Razón (Argentina)… de inmunosupresores con la ciclosporina (Sandimmun), para la prevención del rechazo de órganos. En la actualidad ofrece, además, Certican (everolimus) Myfortic (micofenolato sódico) , Simulect (…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …Sacramento BeeMeanwhile, Biogen and partner Abbott (NYSE:ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is bein…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …PR Newswire (press release)Meanwhile, Biogen and partner Abbott (NYSE: ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Dacl…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …NASDAQMeanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …InvestorIdeas.com (press release)Meanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) i…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …Zacks.comMeanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab …
Cell Therapeutics' lymphoma drug, Pixuvri gets EU conditional marketing approvalpharmabiz.comThe EMA's Committee for Medicinal Products for Human Use (CHMP) has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, wh…
Standard Review for Biogen's BG-12 – Analyst BlogNASDAQMeanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-w…
Standard Review for Biogen's BG-12Zacks.comMeanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or b…